Attention: You are using an outdated browser, device or you do not have the latest version of JavaScript downloaded and so this website may not work as expected. Please download the latest software or switch device to avoid further issues.

News > Research buzz > Delaying second Pfizer-BioNTech dose could leave cancer patients with insufficient immunity

Delaying second Pfizer-BioNTech dose could leave cancer patients with insufficient immunity

Researchers from the Crick and Imperial College have started work on a new study, funded by Kidney Research UK and the National Kidney Federation.
15 Mar 2021
United Kingdom
Research buzz

To view this News Article please log in or create a profile

Similar stories

IMAGE TAKEN FROM THE SPLEEN OF A COVID PATIENT. CYAN SHOWS T CELLS, BLUE SHOWS ALL CELL NUCLEI AND M
Research buzz

Crick-UCL research finds that repurposed drug improves outcomes for patients with severe COVID-19 pn

More...

CREDIT: GREG FINDLAY AND MEGAN BUCKLEY
Researchers map the effects of all potential changes in key cancer gene

More...

NAEVUS, OR MOLE, CELLS IN PINK. CREDIT: DALE BRYANT, JOURNAL OF INVESTIGATIVE DERMATOLOGY.
Researchers find potential of mole reversal therapy in rare condition

More...

A LUNG CANCER CELL - ANNE WESTON, ELECTRON MICROSCOPY
Why many lung cancer patients who have never smoked have worse outcomes

New research from the Crick, UCL and AstraZeneca. More...

Macrophages, a major type of immune cell. Credit: Christina Stankey.
Major cause of inflammatory bowel disease discovered

Researchers have discovered a new biological pathway that is a principal driver of inflammatory bowel disease (IBD) and … More...

Have your say

 
image

Contact us

The Francis Crick Institute
1 Midland Road
London
NW1 1AT

connect@crick.ac.uk


Check out

Community
Mentoring
Careers
News
Groups
Events

Legal

Terms
Privacy
Cookies
About
Contact

This website is powered by
ToucanTech